Biocon and Serum Institute come together with strategic alliance to increase vaccine access for developing countries

As part of the deal, the BBL has offered 15% stake to SILS at a post money valuation of $4.9 billion in exchange for committed access to 100 million doses of vaccines per annul for 15 years.

published on : 18th September 2021

Biocon-Serum alliance to build biotech powerhouse 

Research and manufacturing infrastructure will also be leveraged by this partnership for opportunities in infectious diseases,” Shaw said.

published on : 18th September 2021

Biocon inks patent litigation settlement pact with Celgene over bone marrow cancer medicine

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb.

published on : 8th September 2021

Biocon Biologics partners with Adagio Therapeutics for Covid antibody treatment in India

Initial data indicate that ADG20 could provide both rapid and durable protection against COVID-19 for up to one year, Biocon Biologics said.

published on : 26th July 2021

Insider trading case: Sebi bars Biocon's official from securities market for three months, levies fine

Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018.

published on : 1st July 2021

COVID-19 has created an 'ecosystem' of innovation in India: Biocon chief Kiran Mazumdar-Shaw

Mazumdar-Shaw is one of the key speakers at the 15th edition of the annual virtual summit on June 22 hosted by the USA India Chambers of Commerce.

published on : 15th June 2021

Kiran Mazumdar-Shaw compares Covid-19 vaccination situation in India to arranged marriage

Mazumdar-Shaw, the executive chairperson of biotechnology major Biocon, in a lighter vein compared the two while bringing out the confusion that currently prevails regarding the vaccination process.

published on : 15th May 2021

Biocon ties up with Belagavi firm to produce Remdesivir

A Belagavi-based pharmaceutical company has been roped in to manufacture ‘Remidesvir’, which is given to critical Covid patients and is in short supply across the country.

published on : 2nd May 2021

Biocon Pharma gets GMP compliance certificate from UK's health regulator for Bengaluru facility

The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection in March 22.

published on : 12th April 2021